drugset / Trial / NCT07175493
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NaSequentialOpen-labelTreatment
Summary
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
Timeline
- Start
- 2025-11-18
- Primary completion
- 2027-11-18
- Completion
- 2028-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | — | Subcutaneous |